methamphetamines - Page 1 | CARLAT PUBLISHING

Expert Q&A

Update on Stimulant Use Disorder

October 1, 2024

Brian Hurley, MD, MBA, FAPA, DFASAM

Addiction physician; President of the American Society for Addiction Medicine; Medical Director of the Bureau of Substance Abuse Prevention and Control, Los Angeles County Department of Public Health, Los Angeles, CA.

Dr. Hurley has no financial relationships with companies related to this material.

The interview with Dr. Hurley provides crucial insights into the world of psychostimulants, their misuse, and the emerging Fourth Wave of the Overdose Epidemic. Dr. Hurley discusses everything from the differences between stimulants like methamphetamine and cocaine to the importance of harm reduction strategies and evidence-based treatments for stimulant use disorder.

Clinical Update

Overview of Stimulants

October 1, 2024

Michael Weaver, MD, FASAM and Noah Capurso, MD

Michael Weaver, MD, DFASAM. Professor and Medical Director, Center for Neurobehavioral Research on Addiction at the University of Texas Medical School, Houston, TX.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, and Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Weaver and Capurso have no financial relationships with companies related to this material.

This article offers an insightful overview of the pharmacology of various stimulant drugs, their potential for misuse, and the dangers they pose—especially with rising overdose rates due to contamination with fentanyl. Learn about the history, various classes of stimulants, and the treatments available for stimulant use disorder, as well as the crucial harm reduction strategies aimed at minimizing risks.

Expert Q&A

Substance-Induced Psychosis: Diagnostic Dilemmas and Treatment Options

January 31, 2024

Nicholas Athanasiou, MD, MBA, DFASAM

Nicholas Athanasiou, MD, MBA, DFASAM.

Associate clinical professor, Psychiatry and Biobehavioral Sciences (DGSOM), UCLA Olive View Psychiatry Residency Program; Supervising Mental Health Psychiatrist, Los Angeles County Department of Mental Health, Los Angeles, CA.

Dr. Athanasiou has no financial relationships with companies related to this material.

Substance-induced psychosis (SIP) presents diagnostic challenges in distinguishing it from primary psychotic disorders, with substance timing, symptom type, and duration being key differentiators. Effective treatment combines antipsychotic medications and substance cessation strategies. Dr. Athanasiou reviews key points in the management of SIP.

Research Update

Methamphetamines and Opioid-Related Overdose Risk

April 1, 2023

Peter J. Farago, MD.

Peter J. Farago, MD. Dr. Farago has no financial relationships with companies related to this material.

Researchers provide a detailed glimpse into the chaotic state of the illicit opioid supply and show that the potentially dangerous misconception that methamphetamines can be used as an opioid overdose reversal agent is widespread.

Add-On Buprenorphine for Methamphetamine Use Disorder

March 1, 2022

Sanya Virani, MD.

Sanya Virani, MD. Dr. Virani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are very few medication options shown to be effective for the treatment of methamphetamine use disorder. Here, researchers examine the utility of buprenorphine to reduce drug cravings.

RESEARCH UPDATE

Antipsychotics for Methamphetamine Psychosis

January 18, 2022

Sanya Virani, MD.

Sanya Virani, MD. Dr. Virani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this network meta-analysis, researchers compared different antipsychotics head-to-head for the treatment of methamphetamine psychosis and found some clear winners are losers.